ES2132201T3 - Inhibidores de la hiv proteasa utiles en el tratamiento del sida. - Google Patents

Inhibidores de la hiv proteasa utiles en el tratamiento del sida.

Info

Publication number
ES2132201T3
ES2132201T3 ES93310359T ES93310359T ES2132201T3 ES 2132201 T3 ES2132201 T3 ES 2132201T3 ES 93310359 T ES93310359 T ES 93310359T ES 93310359 T ES93310359 T ES 93310359T ES 2132201 T3 ES2132201 T3 ES 2132201T3
Authority
ES
Spain
Prior art keywords
treatment
aids
protease inhibitors
hiv protease
useful hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93310359T
Other languages
English (en)
Inventor
Louis Nickolaus Jungheim
Timothy Alan Shepherd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/134,329 external-priority patent/US5733906A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2132201T3 publication Critical patent/ES2132201T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS INHIBIDORES DE VIH DE FORMULA I, FORMULAS FARMACEUTICAS QUE CONTIENEN ESTOS COMPUESTOS Y METODOS DE TRATAMIENTO Y/O PREVENCION DE INFECCION DE VIH Y/O SIDA DONDE R ES UN GRUPO QUE TIENE LA FORMULA: R2 ES UNA CADENA LATERAL AMINOACIDA O (CH2)Y-X-R2A; Y ES 0,1 O 2; Y X, R0, R3 E Y1 SON COMO SE DEFINEN EN LA SOLICITUD.
ES93310359T 1992-12-22 1993-12-20 Inhibidores de la hiv proteasa utiles en el tratamiento del sida. Expired - Lifetime ES2132201T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99525692A 1992-12-22 1992-12-22
US08/134,329 US5733906A (en) 1993-10-12 1993-10-12 Inhibitors of HIV Protease useful for the treatment of Aids

Publications (1)

Publication Number Publication Date
ES2132201T3 true ES2132201T3 (es) 1999-08-16

Family

ID=26832220

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93310359T Expired - Lifetime ES2132201T3 (es) 1992-12-22 1993-12-20 Inhibidores de la hiv proteasa utiles en el tratamiento del sida.

Country Status (21)

Country Link
US (1) US5905077A (es)
EP (1) EP0604185B1 (es)
JP (1) JPH06271534A (es)
KR (1) KR940014337A (es)
CN (1) CN1044117C (es)
AT (1) ATE178055T1 (es)
AU (1) AU667146B2 (es)
BR (1) BR9305162A (es)
CA (1) CA2112042A1 (es)
CZ (1) CZ281493A3 (es)
DE (1) DE69324120T2 (es)
ES (1) ES2132201T3 (es)
FI (1) FI935778A7 (es)
HU (1) HUT69693A (es)
IL (1) IL108092A (es)
MX (1) MX9308016A (es)
MY (1) MY131388A (es)
NO (1) NO934719L (es)
NZ (1) NZ250491A (es)
PL (1) PL301581A1 (es)
TW (1) TW262468B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH1649H (en) 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
JPH07504654A (ja) 1992-03-11 1995-05-25 ナルヘックス　リミテッド オキソ及びヒドロキシ置換炭化水素のアミン誘導体
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5461154A (en) * 1994-02-02 1995-10-24 Eli Lilly And Company Intermediate and process for making
TW472047B (en) * 1994-02-04 2002-01-11 Merck & Co Inc Process for making HIV protease inhibitors
US5792869A (en) * 1994-11-04 1998-08-11 Yamakawa Chemical Industry Co., Ltd Process for preparing optically active piperazine derivatives and Intermediates for preparation
US5929284A (en) * 1995-02-03 1999-07-27 Kaneka Corporation Processes for producing α-halo ketones, α-halohydrins and epoxides
US5618937A (en) * 1995-03-15 1997-04-08 Merck & Co., Inc. Process to make HIV protease inhibitor from (2S)-4-picolyl-2-piperazine-t-butylcarboxamide
US6222043B1 (en) 1995-06-30 2001-04-24 Japan Energy Corporation Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
US5932550A (en) * 1995-06-30 1999-08-03 Japan Energy Corporation Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
US6133461A (en) 1995-09-26 2000-10-17 Japan Tobacco Inc. Process for producing amide derivatives and intermediates therefor
DE69637770D1 (de) * 1995-09-26 2009-01-15 Agouron Pharma Verfahren zur herstellung von amidderivaten und ihren zwischenverbindungen
WO1997021690A1 (en) * 1995-11-28 1997-06-19 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
CA2249747A1 (en) 1996-12-27 1998-07-09 Tsutomu Mimoto Novel tripeptide compounds and anti-aids drugs
JP4006058B2 (ja) 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
DK0950416T3 (da) 1997-03-14 2007-02-26 Daiichi Seiyaku Co Anvendelse af TCF-II til behandling af cancerrelateret tab af kropsvægt, anæmi og TNF-forhöjelse
WO2000002862A1 (en) * 1998-07-08 2000-01-20 G.D. Searle & Co. Retroviral protease inhibitors
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
JP4615727B2 (ja) * 1998-12-24 2011-01-19 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ａβタンパク質生成の阻害剤としてのスクシノイルアミノベンゾジアゼピン
US6960576B2 (en) * 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
EP1222176A1 (en) 1999-10-08 2002-07-17 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
US6525044B2 (en) 2000-02-17 2003-02-25 Bristol-Myers Squibb Company Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
MXPA02009729A (es) 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de la proteina a-beta.
AU2001253090A1 (en) * 2000-04-03 2001-10-15 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of abeta protein production
US6632812B2 (en) * 2000-04-11 2003-10-14 Dupont Pharmaceuticals Company Substituted lactams as inhibitors of Aβ protein production
US20100009966A1 (en) * 2001-04-11 2010-01-14 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of abeta protein production
AU2001261728A1 (en) * 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
CA2379445C (en) 2000-06-01 2007-08-21 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
WO2002064553A1 (en) * 2001-02-14 2002-08-22 Kureha Chemical Industry Company, Limited Process for preparation of halogenoalcohol derivatives
US20090062256A1 (en) * 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
GB0123467D0 (en) 2001-09-28 2001-11-21 Hoffmann La Roche Carbocyclic HIV Protease inhibitors
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
CN101508664B (zh) * 2009-02-25 2012-08-22 江阴希迪医药科技有限公司 N-苄氧羰基-3-氨基-1-氯-4-苯硫基-2-丁醇合成方法
SG186821A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
CN105121418A (zh) 2012-04-20 2015-12-02 吉利德科学公司 苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
ES2243959T3 (es) * 1990-11-19 2005-12-01 Monsanto Company Inhibidores de proteasas retrovirales.
HUT60282A (en) * 1991-02-08 1992-08-28 Sankyo Co Process for producing new beta-amino-alpha-hydroxycarboxylic acid derivatives and pharmaceutical compositions comprising such compounds
US5430041A (en) * 1991-05-10 1995-07-04 Hoffmann-La Roche Inc. Amino acid derivatives having antiviral activity
CN1071930A (zh) 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
WO1993013066A1 (en) 1991-12-20 1993-07-08 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
US5312820A (en) * 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines

Also Published As

Publication number Publication date
MY131388A (en) 2007-08-30
AU667146B2 (en) 1996-03-07
US5905077A (en) 1999-05-18
AU5252893A (en) 1994-07-07
CA2112042A1 (en) 1994-06-23
MX9308016A (es) 1994-08-31
NZ250491A (en) 1995-08-28
TW262468B (es) 1995-11-11
DE69324120D1 (de) 1999-04-29
HUT69693A (en) 1995-09-28
CZ281493A3 (en) 1994-07-13
DE69324120T2 (de) 1999-11-25
PL301581A1 (en) 1994-06-27
NO934719D0 (no) 1993-12-20
FI935778A7 (fi) 1994-06-23
NO934719L (no) 1994-06-23
IL108092A0 (en) 1994-04-12
EP0604185A1 (en) 1994-06-29
FI935778A0 (fi) 1993-12-21
IL108092A (en) 1998-06-15
CN1094399A (zh) 1994-11-02
BR9305162A (pt) 1994-11-01
EP0604185B1 (en) 1999-03-24
ATE178055T1 (de) 1999-04-15
CN1044117C (zh) 1999-07-14
JPH06271534A (ja) 1994-09-27
KR940014337A (ko) 1994-07-18

Similar Documents

Publication Publication Date Title
ES2132201T3 (es) Inhibidores de la hiv proteasa utiles en el tratamiento del sida.
ES2150933T3 (es) Inhibidores de la proteasa vih utiles para el tratamiento del sida.
ES2101252T3 (es) Inhibidores de la proteasa del hiv utiles para el tratamiento del sida.
ES2177868T3 (es) Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
MX9403380A (es) Inhibidores de proteasa de vih utiles para el tratamiento de sida.
ES2125251T3 (es) Inhibidores de la proteasa del vih.
ES2181725T3 (es) Inhibidores de hiv proteasa.
ES2103249T1 (es) Procedimiento y composicion para inhibir el crecimiento de microorganismos incluyendo acido peracetico y un biocida no oxidante.
ES2112880T3 (es) Inhibidores de la proteasa de vih utiles para el tratamiento del sida.
SG52628A1 (en) Substituted cyclic carbonyls and derivatives thereof useful as retrobiral protease inhibitors
ES2174921T3 (es) Inhibidores de la proteasa del vih.
ES2183817T3 (es) Inibidores de proteasas de parasatiso metazoarios.
MX9308025A (es) Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
CO4130200A1 (es) Inhibidores de proteasa del hiv utiles en el tratamiento del sida
ES2096874T3 (es) Inhibidor de la proteasa de hiv util para el tratamiento del sida.
PT817624E (pt) Inibidores de proteases de parasitas metazoarios
ES2190456T3 (es) Combinacion de inhibidores de la proteasa del vih.
MX9304351A (es) Inhibidores de proteasas de aminodiol y composiciones farmaceuticas que los incluyen.
RU93055683A (ru) Ингибиторы вич-протеазы, способ их получения, их использование, композиция
RU93055680A (ru) Ингибиторы вич-протеазы, способ получения, их использование, композиция
RU93055681A (ru) Ингибиторы вич-протеазы, способ их получения, их использование в фармкомпозициях

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 604185

Country of ref document: ES